Activation of PI3K pathway has been described as a mechanism of resistance to hormone therapy and anti-HER2 therapy in breast cancer [100], clinical trials of combinations of these agents with PI3K inhibitors are currently ongoing. Here, PIK3CA is linked to breast cancer.